$JNCE Target $17 By March 2022
Jounce Therapeutics Inc. is a clinical-stage immunotherapy company that focuses on developing cancer treatments that aide the patient's immune system in attacking the tumors. This is completely revolutionizing the way we treat cancer, and this company has plenty of room to grow. Target $17 within the next year or so. However, that is only in the next year. Jounce could easily be retesting ATH's by 2026, maybe sooner. Like and follow :) Happy Trading!
Publikasi terkait
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.